Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Pediatr Nephrol. 2013 Apr;28(4):577-82. doi: 10.1007/s00467-012-2336-0. Epub 2012 Nov 2.


Fibroblast growth factor 23 (FGF23) is an "endocrine" FGF acting in the kidney as a phosphaturic hormone and a suppressor of active vitamin D, through an inhibition of the 1α hydroxylase and a stimulation of the 24 hydroxylase. Beyond its well-known effects on the bone/kidney/parathyroid axis and its deregulation during chronic kidney disease (CKD), recent evidence has revealed its direct systemic effects on cardiovascular health. In the meantime, studies have highlighted the health implications for vitamin D inside and outside CKD that also extend beyond its classical actions on mineral homeostasis and bone metabolism: vitamin D has indeed been shown to exert pluripotent non-classical effects as a modulator of immune function in monocytes, mainly through the stimulation of the antimicrobial cathelicidin. The aim of this review is to provide new insights on the interplay between FGF23 and vitamin D in innate immunity in the context of CKD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone Remodeling*
  • Bone and Bones / metabolism*
  • Bone and Bones / physiopathology
  • Fibroblast Growth Factors / metabolism*
  • Glucuronidase / metabolism
  • Humans
  • Immunity, Innate*
  • Monocytes / immunology
  • Monocytes / metabolism*
  • Myocytes, Cardiac / metabolism
  • Renal Insufficiency, Chronic / immunology
  • Renal Insufficiency, Chronic / metabolism*
  • Renal Insufficiency, Chronic / physiopathology
  • Signal Transduction
  • Vitamin D / metabolism*


  • Vitamin D
  • Fibroblast Growth Factors
  • fibroblast growth factor 23
  • Glucuronidase
  • klotho protein